Oncotarget

Reviews:

mTOR pathway in colorectal cancer: an update

Maria Giovanna Francipane _ and Eric Lagasse

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:49-66. https://doi.org/10.18632/oncotarget.1548

Metrics: PDF 4361 views  |   HTML 4712 views  |   ?  


Abstract

Maria Giovanna Francipane1,2 and Eric Lagasse1

1 McGowan Institute for Regenerative Medicine, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

2 Ri.MED Foundation, Palermo, Italy.

Correspondence:

Eric Lagasse, email:

Keywords: mTOR, colorectal cancer, cancer stem-like cells, personalized medicine.

Received: October 28, 2013 Accepted: December 3, 2013 Published: December 5, 2013

Abstract

The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition, next-generation mTOR inhibitors have become available, marking an exciting new phase in mTOR-based therapy. However, the verdict on their therapeutic effectiveness remains unclear. Here we review phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling as one of the primary mechanisms for sustaining tumor outgrowth and metastasis, recent advances in the development of mTOR inhibitors, and current studies addressing mTOR activation/inhibition in colorectal cancer (CRC). We will also discuss our recent comparative study of different mTOR inhibitors in a population of colon cancer stem cells (CSCs), and current major challenges for achieving individualized drug therapy using kinase inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1548